Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R.

J Clin Med. 2019 Jul 16;8(7). pii: E1038. doi: 10.3390/jcm8071038.

2.

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.

Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R.

Sci Rep. 2016 Sep 13;6:32992. doi: 10.1038/srep32992.

3.

Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma.

Lennon FE, Cianci GC, Kanteti R, Riehm JJ, Arif Q, Poroyko VA, Lupovitch E, Vigneswaran W, Husain A, Chen P, Liao JK, Sattler M, Kindler HL, Salgia R.

Sci Rep. 2016 Apr 15;6:24578. doi: 10.1038/srep24578.

4.

FAK and paxillin, two potential targets in pancreatic cancer.

Kanteti R, Batra SK, Lennon FE, Salgia R.

Oncotarget. 2016 May 24;7(21):31586-601. doi: 10.18632/oncotarget.8040. Review.

5.

Extracellular Vesicles from Caveolin-Enriched Microdomains Regulate Hyaluronan-Mediated Sustained Vascular Integrity.

Mirzapoiazova T, Lennon FE, Mambetsariev B, Allen M, Riehm J, Poroyko VA, Singleton PA.

Int J Cell Biol. 2015;2015:481493. doi: 10.1155/2015/481493. Epub 2015 Sep 10.

6.

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.

Mirzapoiazova T, Mambetsariev N, Lennon FE, Mambetsariev B, Berlind JE, Salgia R, Singleton PA.

Front Oncol. 2015 Jul 21;5:164. doi: 10.3389/fonc.2015.00164. eCollection 2015.

7.

Lung cancer-a fractal viewpoint.

Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R.

Nat Rev Clin Oncol. 2015 Nov;12(11):664-75. doi: 10.1038/nrclinonc.2015.108. Epub 2015 Jul 14. Review.

8.

MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.

Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R.

PLoS One. 2014 Sep 15;9(9):e105919. doi: 10.1371/journal.pone.0105919. eCollection 2014.

9.

Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.

Lennon FE, Mirzapoiazova T, Mambetsariev N, Mambetsariev B, Salgia R, Singleton PA.

J Biol Chem. 2014 Aug 29;289(35):24043-58. doi: 10.1074/jbc.M114.554766. Epub 2014 Jul 14.

10.

The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.

Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, Singleton PA.

PLoS One. 2014 Mar 24;9(3):e91577. doi: 10.1371/journal.pone.0091577. eCollection 2014.

11.

Mitochondrial dynamics: biology and therapy in lung cancer.

Lennon FE, Salgia R.

Expert Opin Investig Drugs. 2014 May;23(5):675-92. doi: 10.1517/13543784.2014.899350. Epub 2014 Mar 22. Review.

PMID:
24654596
12.

Intermittent hypoxia-induced changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep apnea.

Almendros I, Wang Y, Becker L, Lennon FE, Zheng J, Coats BR, Schoenfelt KS, Carreras A, Hakim F, Zhang SX, Farré R, Gozal D.

Am J Respir Crit Care Med. 2014 Mar 1;189(5):593-601. doi: 10.1164/rccm.201310-1830OC.

13.

Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer.

Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand TM, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R.

Cancer Biol Ther. 2013 Jul;14(7):679-91. doi: 10.4161/cbt.25091. Epub 2013 May 31.

14.

The μ-opioid receptor in cancer progression: is there a direct effect?

Lennon FE, Moss J, Singleton PA.

Anesthesiology. 2012 Apr;116(4):940-5. doi: 10.1097/ALN.0b013e31824b9512. Review. No abstract available.

PMID:
22357347
15.

Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.

Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA.

Anesthesiology. 2012 Apr;116(4):857-67. doi: 10.1097/ALN.0b013e31824babe2.

PMID:
22343475
16.

Hyaluronan regulation of vascular integrity.

Lennon FE, Singleton PA.

Am J Cardiovasc Dis. 2011;1(3):200-13. Epub 2011 Sep 10.

17.

Acute Lung Injury Regulation by Hyaluronan.

Singleton PA, Lennon FE.

J Allergy Ther. 2011 Dec 20;Suppl 4. doi: 10.4172/2155-6121.S4-003.

18.

Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology.

Lennon FE, Singleton PA.

Am J Physiol Lung Cell Mol Physiol. 2011 Aug;301(2):L137-47. doi: 10.1152/ajplung.00071.2010. Epub 2011 May 13. Review.

19.

The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation.

Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA.

Anesth Analg. 2011 Mar;112(3):558-67. doi: 10.1213/ANE.0b013e31820568af. Epub 2010 Dec 14.

20.

High-molecular-weight hyaluronan is a novel inhibitor of pulmonary vascular leakiness.

Singleton PA, Mirzapoiazova T, Guo Y, Sammani S, Mambetsariev N, Lennon FE, Moreno-Vinasco L, Garcia JG.

Am J Physiol Lung Cell Mol Physiol. 2010 Nov;299(5):L639-51. doi: 10.1152/ajplung.00405.2009. Epub 2010 Aug 13.

Supplemental Content

Loading ...
Support Center